IR-Med appoints Ran Ziskind as CEO effective September 1, 2024

IR-Med, Inc.

Ran Ziskind replaces Ronnie Klein, who was interim CEO and remains CTO.
Ziskind receives 1,400,000 restricted shares at $0.58/share, vesting over 4 years.
Salary: NIS 6,000/month until $4M funding raised, then NIS 45,000/month plus NIS 10,000 car.
Ziskind co-founded Galatea Ltd., later acquired by Sarin Technologies; background in electro-optics.
PressureSafe product ready to launch; pipeline includes other noninvasive diagnostic indications.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ran Ziskind

Chief Executive Officer

IR-Med, Inc.

Effective: 2024-09-01
Filed: August 28, 2024, 7:59 PM ET

On August 21, 2024, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Mr. Ran Ziskind to serve as its Chief Executive Officer (CEO), replacing Mr. Ronnie Klein, who had been serving as Interim CEO, effective September 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ran Ziskind was appointed as Chief Executive Officer at IR-Med, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On August 21, 2024, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Mr. Ran Ziskind to serve as its Chief Executive Officer (CEO), replacing Mr. Ronnie Klein, who had been serving as Interim CEO, effective September 1, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-034186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.